Pasithea Therapeutics Announces Activation of Clinical Trial Sites
Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotechnology company at the forefront of drug development, is thrilled to reveal the activation of two clinical trial sites in South Korea. This initiative focuses on their investigational drug, PAS-004, which is entering a Phase 1/1b open-label study. The trial aims to evaluate the safety and effect of PAS-004 on adult patients suffering from neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas that are either inoperable, incompletely resected, or recurrent.
Details of the Clinical Trial
The selected sites for recruiting participants include ASAN Medical Centre and Severance Hospital Yonsei University Health System. These renowned institutions are pivotal in nurturing a pool of NF1 patients who can benefit from this innovative treatment. Professor Lee Beom-Hee, from ASAN Medical Centre, expressed enthusiasm about the collaboration with Pasithea, highlighting the center's extensive experience and leadership in researching NF1 conditions. With a significant number of NF1 cases in South Korea, both sites are strategically positioned to support this groundbreaking trial.
The Role of PAS-004
PAS-004 represents a next-generation macrocyclic MEK inhibitor specifically designed to combat RASopathies and MAPK pathway-driven tumors. By inhibiting MEK, PAS-004 addresses the underlying mechanisms causing tumor growth in patients with NF1. Dr. Tiago Reis Marques, CEO of Pasithea, remarked on the importance of this trial, stating that with an approximate 10,000 NF1 patients in South Korea, this study holds promise for enhancing treatment options and improving patient outcomes.
Trial Objectives and Phases
The Phase 1/1b trial has a dual focus: to assess the safety and tolerability of PAS-004 as well as to evaluate its pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Part A of the trial will involve a dose escalation strategy with a maximum of 24 participants receiving varying levels of PAS-004, aiming to establish an optimal dosage guideline. Meanwhile, Part B will expand to include more participants to facilitate further exploration of PAS-004's effectiveness.
Potential Impact on Quality of Life
In addition to understanding the drug's physical effects, the trial emphasizes the importance of quality of life (QOL) assessments for participants. Evaluating the potential of PAS-004 to alleviate symptoms and improve the day-to-day lives of NF1 patients is a fundamental aspect of the study.
Pasithea's Vision for the Future
Pasithea Therapeutics remains committed to leading advancements in biotechnology with its core vision centered around transforming health outcomes for those affected by RASopathies. By including both Australian and South Korean sites, the company is poised to recruit a diverse participant pool to facilitate enriched data for this clinical trial.
About Pasithea Therapeutics Corp.
With its headquarters aiming to innovate treatments, Pasithea Therapeutics is devoted to developing its pioneering drug candidate, PAS-004, with the goal to make significant strides in addressing both rare and prevalent conditions. Their ongoing trials underscore their dedication to a future where advanced treatment options are accessible to all patients.
Frequently Asked Questions
What is the goal of the Phase 1/1b clinical trial?
The trial aims to evaluate the safety, tolerability, and preliminary efficacy of PAS-004 in treating adult NF1 patients with plexiform neurofibromas.
Where are the clinical trial sites located?
Clinical trial sites are activated at ASAN Medical Centre and Severance Hospital Yonsei University Health System in South Korea.
How many patients are involved in the trial?
Up to 48 eligible participants will be included across both phases of the trial.
What are the planned phases of the trial?
The trial consists of two parts: Part A focuses on dose escalation, while Part B is the expansion phase exploring the identified dosage further.
What does Pasithea Therapeutics focus on?
Pasithea Therapeutics specializes in developing next-generation therapies targeting RASopathies, with PAS-004 being a key candidate aimed at improving patient health outcomes.
